fbpx

Cancer Patient Experience: engagement, needs and more

CareAcross provides personalised support services for patients with cancer. Their focus is on sharing research findings and guidelines, and offer evidence-based approaches to improve quality of life for those living with cancer, whilst strengthening the relationship between the patient and their medical team. 

CareAcross engages with thousands of patients diagnosed with many different cancers, providing services around patient engagement, real world evidence, clinical trial recruitment, and patient-reported outcomes.

The relationship between a patient and their doctor is unique, especially when it is about cancer. CareAcross set out to identify the needs and priorities of patients regarding this critical aspect of their experience with cancer.

M3 regularly partners with CareAcross by giving their members the opportunity to take part in our research studies and share their opinion on existing, and future, oncological therapies.

We partnered with CareAcross on this survey which aims to understand the needs of patients affected by different types of cancer.

Breast: side-effects & nutrition are top needs; also survivorship. Lung: need guidance on nutrition & exercise, as well as side-effects. Prostate: many unmet needs overall. Colorectal: nutrition & exercise needs; better supported overall

Take part in paid market research studies with us

Leave a Reply

Join Today

Registration is free and only takes a few clicks

Panel Members

Check your available studies

latest posts

cancer treatment - oncology - targeted therapy - immunotherapy - chemotherapy

Cancer Treatment Advancements: 2023 Oncology Highlights

New technologies and advancements in hormone therapy, immunotherapy, and targeted therapy are transforming the oncology treatment landscape. Here are some of the important oncology developments and new FDA-approved cancer drugs during 2023.

Discover more from M3 Global Research Blog

Subscribe now to keep reading and get access to the full archive.

Continue reading